Form 4: CARGO Therapeutics Director's Option Disposition

A director of CARGO Therapeutics, Kapil Dhingra, disposed of 25,000 stock options following the company's merger with Concentra Biosciences.

Summary

• Kapil Dhingra, a Director of CARGO Therapeutics, Inc. (CRGX), reported the disposition of 25,000 stock options.
• This disposition occurred on August 19, 2025, as a result of the merger between CARGO Therapeutics, Inc. and Concentra Biosciences, LLC.
• The merger involved a tender offer completed on August 18, 2025, where outstanding shares were acquired for $4.379 per share in cash plus one contingent value right (CVR).
• Stock options, including Dhingra's with an exercise price of $4.35, became fully vested and were converted into cash (equal to the difference between the cash offer price and the exercise price) and one CVR per underlying share.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and the orderly disposition of insider stock options as per the merger agreement, indicating a positive and expected outcome for the company's acquisition.

Positives

• The merger resulted in options becoming fully vested and exercisable.
• Options with an exercise price below the cash offer price were converted into cash and CVRs, providing value to option holders.

Negatives

• Options with an exercise price equal to or greater than the cash offer price were canceled for no consideration.
• CARGO Therapeutics, Inc. is no longer a publicly traded company, having become a wholly-owned subsidiary of Concentra Biosciences, LLC.

Future Outlook

The filing does not provide any forward-looking statements or guidance, as it is a report of a completed insider transaction following a merger.

Industry Context

The filing indicates a successful acquisition of a biotechnology company (CARGO Therapeutics) by Concentra Biosciences, a common trend in the pharmaceutical and biotech sectors where larger entities acquire smaller, specialized firms for their pipeline or technology.

Comparison to Industry Standards

• The acquisition price of $4.379 per share plus a CVR suggests a valuation based on current assets and potential future milestones, typical for biotech acquisitions where CVRs are used to bridge valuation gaps for pipeline assets.
• The use of a tender offer followed by a short-form merger is a standard acquisition mechanism in the U.S. for public companies.
• The treatment of stock options, including accelerated vesting and cash-out/CVR conversion, aligns with common practices in M&A transactions to ensure employee and director incentives are addressed.

Stakeholder Impact

• Shareholders: Received $4.379 cash per share plus one CVR.
• Option Holders (including Kapil Dhingra): Options vested and converted to cash and CVRs (if in-the-money) or canceled (if out-of-the-money).
• Company: CARGO Therapeutics, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC.

Key Dates

Recommendation

CARGO Therapeutics, Inc. has been acquired by Concentra Biosciences, LLC and is no longer a publicly traded entity. Shareholders received cash and contingent value rights (CVRs) as part of the merger consideration. The CVRs represent potential future value based on specific milestones, but the common stock itself is no longer traded, making traditional buy/sell recommendations irrelevant. A 'hold' recommendation applies to the CVRs, if an investor holds them, awaiting their potential payout.

Keywords

CARGO Therapeutics, CRGX, Kapil Dhingra, SEC Form 4, Insider Trading, Stock Options, Merger, Tender Offer, Concentra Biosciences, Contingent Value Right, CVR